Prog Cardiovasc Nurs. 2007 Spring;22(2):97–100. 10. Lee CR, Thrasher click here KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy. 2001;21(10):1240–6.PubMedCrossRef 11. Casner PR. Inability to attain oral
anticoagulation: warfarin-rifampin interaction revisited. South Med J. 1996;89(12):1200–3.PubMedCrossRef 12. Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z. Complex interaction of rifampin and warfarin. South Med J. 1988;81(10):1304–6.PubMedCrossRef 13. Self TH, Mann RB. Interaction of rifampin and warfarin. Chest. 1975;67(4):490–1.PubMedCrossRef 14. Romankiewicz JA, Ehrman M. Rifampin and warfarin: a drug interaction. Ann Intern Med. 1975;82(2):224–5.PubMedCrossRef 15. World Health Organization. Treatment of tuberculosis guidelines. Fourth Edition. 2010. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.
Accessed 22 July 2013. 16. World Health Organization. Global Tuberculosis Ivacaftor purchase Report 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf. Accessed 22 July 2013. 17. Division of Leprosy, Tuberculosis and Lung Disease. DLTLD Guidelines on management of leprosy and tuberculosis. March 2009. http://www.nltp.co.ke/docs/DLTLD_Treatment_Guidelines.pdf. Accessed 22 July 2013. 18. Pastakia SD, Crisp WI, Schellhase EM, et al. Implementation of a pharmacist managed anticoagulation clinic in Eldoret, Kenya. South Med Rev. 2010;3:20–3. 19. Manji I, Pastakia SD, DO AN, et al. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215–20.PubMedCrossRef 20. Pastakia SD, Schellhase EM, Jakait B. Collaborative partnership for clinical pharmacy services in Kenya. Am Meloxicam J Health Syst Pharm. 2009;66:1386–90.PubMedCrossRef 21. Ansell J, Hirsh J, Hylek E, et al. American College of Chest Physicians. Pharmacology and management
of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–98S. 22. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–9.PubMed 23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.PubMedCrossRef 24. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362–72.PubMed 25. Payne JH. Aspects of anticoagulation in children. Br J Haematol. 2010;150:259–77.PubMedCrossRef 26. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999;94:3007–14.PubMed 27. Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.